Company launches automated hematology analyzers in US
Sysmex America, Inc. has launched its XN-L™ automated hematology analyzers in the US.
The company says this new, smaller XN-L line delivers the same clinical and operational value as its XN-Series™ to lower-volume hematology laboratories.
“The XN-Series has been our flagship hematology analyzer line, and, today, we expand our offering by introducing the XN-L Series to meet the demands of lower-volume facilities,” said Andy Hay, chief operating officer of Sysmex America.
“With an XN-L analyzer, clinicians can rely upon the same expanded complete blood count (CBC) featured in our XN-Series analyzers to assess and monitor patients. This expanded CBC goes well beyond the 3-part differential that is currently available to most of the low-volume segment today and can aid in the assessment of sepsis and other hematological disorders.”
The XN-L automated hematology analyzers offer a 6-part differential, including immature granulocyte analysis on each sample.
In addition, the XN-L Series offers optional software licenses for (1) a reticulocyte channel to aid in anemia management and (2) body fluid cell counts.
The XN-L analyzers will also be the first to feature BeyondCare Quality Monitor, a new approach to quality assurance.
“BeyondCare Quality Monitor, a Sysmex proprietary innovation, is a leading-edge, evidence-based QC and calibration verification management program that partners Sysmex with the laboratory to proactively monitor quality assurance metrics,” Hay said. “It will be standard on all XN-L hematology analyzers.
Additional information on XN-L analyzers is available on the Sysmex website at www.sysmex.com/XNL.
The XN-L analyzers will be available both directly through the company and through its distribution partners. Interested parties should contact their Sysmex representative or Sysmex distributor for complete details. 